Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | CPN1 | P15169 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945718 | 0.86 | CYP2C19 (0.49) | CYP2C19CPN1CPB2HDAC4HDAC7 | |
| SCHEMBL17080066 | 0.83 | CYP2C19 (0.61) | CYP2C19CPN1CPB2CES2CES1 | |
| SCHEMBL1458050 | 0.81 | CYP2C19 (1.00) | CYP2C19CPN1CPB2EPHX1 | |
| SCHEMBL666893 | 0.81 | CYP2C19 (1.00) | CYP2C19CPN1CPB2EPHX1 | |
| SCHEMBL1458057 | 0.81 | CYP2C19 (1.00) | CYP2C19CPN1CPB2EPHX1 | |
| SCHEMBL14445157 | 0.81 | CYP2C19 (0.68) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL17080058 | 0.81 | CYP2C19 (0.68) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL4023453 | 0.81 | CYP2C19 (0.68) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL7469210 | 0.81 | CYP2C19 (0.73) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL4025829 | 0.81 | CYP2C19 (0.62) | CYP2C19CPN1CPB2CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116877-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | CYP2C19 245/4885CPN1 1262/4885CPB2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.